EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial

Michael Arzt, Henrik Fox iD, Stefan Stadler, Andrea Hetzenecker, Olaf Oldenburg, Okka W Hamer, Florian Poschenrieder iD, Clemens Wiest, Radu Tanacli, Sebastian Kelle, Leonhard Bruch, Mirko Seidel und 4 weitere

European Respiratory Journal · 2024

DOI: 10.1183/13993003.02338-2023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Michael Arzt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany michael.arzt@klinik.uni-regensburg.de. Hauptthemen laut MEDLINE: Sleep Apnea Syndromes, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: ResMed Foundation, ResMed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sleep disordered breathing (SDB) has been associated with less myocardial salvage and smaller infarct size reduction after acute myocardial infarction (AMI). The Treatment of sleep apnoea Early After Myocardial infarction with Adaptive Servo-Ventilation (TEAM-ASV I) trial investigated the effects of adding adaptive servo-ventilation (ASV) for SDB to standard therapy on the myocardial salvage index (MSI) and change in infarct size within 12 weeks after AMI.

Methods

In this multicentre, randomised, open-label trial, patients with AMI and successful percutaneous coronary intervention within 24 h after symptom onset plus SDB (apnoea–hypopnoea index ≥15 events·h −1 ) were randomised to standard medical therapy alone (control) or plus ASV (starting 3.6±1.4 days post-AMI). The primary outcome was the MSI at 12 weeks post-AMI. Cardiac magnetic resonance (CMR) imaging was performed at ≤5 days and 12 weeks after AMI.

Results

76 individuals were enrolled from February 2014 to August 2020; 39 had complete CMR data for analysis of the primary end-point. The MSI was significantly higher in the ASV versus control group (difference 14.6% (95% CI 0.14–29.1%); p=0.048). At 12 weeks, absolute (6.6 (95% CI 4.8–8.5) versus 2.8 (95% CI 0.9–4.8) % of left ventricular mass; p=0.003) and relative (44 (95% CI 30–57) versus 21 (95% CI 6–35) % of baseline; p=0.013) reductions in infarct size were greater in the ASV versus control group. No serious treatment-related adverse events occurred.

Conclusions

Early treatment of SDB with ASV improved the MSI and decreased infarct size at 12 weeks after AMI. Larger randomised trials are required to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea SyndromesMyocardial InfarctionPercutaneous Coronary InterventionHumansMaleFemaleMiddle AgedAgedProof of Concept StudyTreatment OutcomeMagnetic Resonance Imaging

Autor:innen und Institutionen

  • Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany michael.arzt@klinik.uni-regensburg.de.
  • Clinic for General and Interventional Cardiology/Angiology Heart and Diabetes Center, NRW Ruhr University Bochum, Bad Oeynhausen, Germany.
  • Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
  • Center for Pneumology, Donaustauf Hospital, Donaustauf, Germany.
  • Center for Cardiology, Ludgerus-Kliniken, Münster, Germany.
  • Department of Radiology, University Hospital Regensburg, Regensburg, Germany.

ORCID-Profile: Henrik Fox, Florian Poschenrieder

Förderung

  • ResMed Foundation
  • ResMed

Zitieren

APA

Arzt, M., Fox, H., Stadler, S., Hetzenecker, A., Oldenburg, O., Hamer, O. W., Poschenrieder, F., Wiest, C., Tanacli, R., Kelle, S., Bruch, L., Seidel, M., Koller, M., Zeman, F., Buchner, S., & TEAM-ASV I Investigators (2024). Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial. European Respiratory Journal. https://doi.org/10.1183/13993003.02338-2023

Vancouver

Arzt M, Fox H, Stadler S, Hetzenecker A, Oldenburg O, Hamer OW, et al. Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial. European Respiratory Journal. 2024. doi:10.1183/13993003.02338-2023

BibTeX
@article{Arzt2024,
  author = {Arzt, Michael and Fox, Henrik and Stadler, Stefan and Hetzenecker, Andrea and Oldenburg, Olaf and Hamer, Okka W and Poschenrieder, Florian and Wiest, Clemens and Tanacli, Radu and Kelle, Sebastian and Bruch, Leonhard and Seidel, Mirko and Koller, Michael and Zeman, Florian and Buchner, Stefan and TEAM-ASV I Investigators, TEAM-ASV I Investigators},
  title = {Treatment of sleep apnoea early after myocardial infarction with adaptive servo-ventilation: a proof-of-concept randomised controlled trial},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.02338-2023}
}
Kostenlos starten →